TY - JOUR
T1 - Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel
AU - Omlin, Aurelius
AU - Sartor, Oliver
AU - Rothermundt, Christian
AU - Cathomas, Richard
AU - De Bono, Johann S
AU - Shen, Liji
AU - Su, Zhen
AU - Gillessen, Silke
N1 - Copyright © 2015 Elsevier Inc. All rights reserved.
PY - 2015/8
Y1 - 2015/8
N2 - INTRODUCTION: We hypothesized that the adverse event (AE) profile of cabazitaxel with regard to alopecia, nail changes, neuropathy, and dysgeusia differs from docetaxel.MATERIALS AND METHODS: Prospectively collected data on treatment-emergent AEs (frequency and grade [G]) from clinical trial databases of docetaxel every 3 weeks (q3w) (in TAX327 and VENICE) and cabazitaxel q3w (in TROPIC) were analyzed.RESULTS: The frequency of new or worsening AEs (all G and G3-4) for 1301 patients was significantly less for alopecia, nail changes, neuropathy, and dysgeusia for cabazitaxel compared with docetaxel.CONCLUSION: Treatment with cabazitaxel might cause less alopecia, nail changes, neuropathy, and dysgeusia compared with docetaxel.
AB - INTRODUCTION: We hypothesized that the adverse event (AE) profile of cabazitaxel with regard to alopecia, nail changes, neuropathy, and dysgeusia differs from docetaxel.MATERIALS AND METHODS: Prospectively collected data on treatment-emergent AEs (frequency and grade [G]) from clinical trial databases of docetaxel every 3 weeks (q3w) (in TAX327 and VENICE) and cabazitaxel q3w (in TROPIC) were analyzed.RESULTS: The frequency of new or worsening AEs (all G and G3-4) for 1301 patients was significantly less for alopecia, nail changes, neuropathy, and dysgeusia for cabazitaxel compared with docetaxel.CONCLUSION: Treatment with cabazitaxel might cause less alopecia, nail changes, neuropathy, and dysgeusia compared with docetaxel.
KW - Alopecia/epidemiology
KW - Clinical Trials as Topic
KW - Docetaxel
KW - Drug-Related Side Effects and Adverse Reactions/epidemiology
KW - Dysgeusia/epidemiology
KW - Humans
KW - Male
KW - Nail Diseases/epidemiology
KW - Peripheral Nervous System Diseases/epidemiology
KW - Prospective Studies
KW - Prostatic Neoplasms/drug therapy
KW - Retrospective Studies
KW - Taxoids/administration & dosage
U2 - 10.1016/j.clgc.2015.01.010
DO - 10.1016/j.clgc.2015.01.010
M3 - Article
C2 - 25733056
VL - 13
SP - e205-e208
JO - Clinical Genitourinary Cancer: prostate, kidney, & bladder
JF - Clinical Genitourinary Cancer: prostate, kidney, & bladder
SN - 1558-7673
IS - 4
ER -
